Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 10Melanoma 8Lung Neoplasms 8Neoplasms 7Carcinoma 6Skin Neoplasms 5Neoplasm Metastasis 5Carcinoma, Squamous Cell 5Carcinoma, Basal Cell 5Adenocarcinoma 5Mouth Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Sarcoma 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Rectal Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Hemangiosarcoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Adrenocortical Carcinoma 2

Interventions

Cisplatin 18Specimen Handling 10Radiotherapy 10Cetuximab 10Magnetic Resonance Spectroscopy 9Radiotherapy, Intensity-Modulated 8Carboplatin 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6Platinum 6Paclitaxel 5Drug Therapy 5Celecoxib 5cemiplimab 4X-Rays 4Surgical Procedures, Operative 4Radiation 4Fluorouracil 4Biopsy 4Taxes 3Standard of Care 3Docetaxel 3durvalumab 2Radiotherapy, Image-Guided 2RRx-001 2Practice Guidelines as Topic 2Observation 2Nivolumab 2Injections 2Fenretinide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Mouth Neoplasms × cemiplimab × Clear all
NCT06448026 2026-05-20

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Recruiting
17 enrolled
Head & Neck

Mouth Neoplasms

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06980038 2026-05-13

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡